Press release
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of
About this update from Siga Technologies Inc.
[{"type":"text","content":"- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Months of 2021 - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2021. “SIGA’s financial results for the first nine months of 2021 include approximately $13 million of international sales, which represents a more than fourfold increase in comparison to the comparable period in 2020. Additionally, we continue to work with Meridian in a new foreign jurisdiction toward finalizing an order that would be similar in size to the initial orders received from Canada in 2020 and early 2021. The timing of the completion of the order has been and may continue to be impacted by the COVID-19 pandemic,” said Phil Gomez, CEO of SIGA. “Looking forward to the fourth quarter of 2021, we are coordinating with our supply chain to deliver up to approximately $113 million in total of oral TPOXX® to the U.S. government, almost 30% of which was delivered in October. This progress highlights the strong and growing revenue base of TPOXX, as well as its continuing importance in orthopox health security preparedness.” Summary Financial Results($ in millions, except per share amounts) Third Quarter 2021 in comparison to Third Quarter 2020 Three Months Ended September 30,2021 Three MonthsEndedSeptember 30,2020Total RevenuesOperating (Loss)/Income (1)(Loss)/Income before Income Taxes (1)Net (Loss)/Income Diluted (Loss)/Income per Share$4.8($2.9)($4.0)($3.1)($0.04) per share $44.3$32.9$31.6$24.2$0.31 per share Nine Months Ended September 30, 2021 in comparison to Nine Months Ended September 30, 2020 Nine Months EndedSeptember 30,2021 Nine Months EndedSeptember 30,2020Total RevenuesOperating (Loss)/Income (1)(Loss)/Income before Income Taxes (1)Net (Loss)/Income Diluted (Loss)/Income per Share$18.3($4.9)($4.6)($3.8)($0.05) per share $87.2$57.7$47.3$36.2$0.45 per share (1) Operating (Loss)/Income excludes, and (Loss)/Income before Income Taxes includes, costs in connection with the retirement of the Company’s term loan, interest expense, interest income and...